Patent · US Expired

Proteins with a high immunoreactivity and a method for the production thereof

US7264805B2 · kind B2 · utility

2Cited by

6References

8Claims

0Family size

Assignee

Scintec Diagnostics · CH

Inventors

Ivan Benes · Forch, CH
Silke Thomsen-Bosslet · Berlin, DE

Key dates

Filing date	Apr 4, 2001
Grant date	Sep 4, 2007
Priority date	—
Expiry date	Oct 24, 2021

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to (glyco-) proteins, in particular monoclonal antibodies, which have an immunoreactivity of >81%, preferably >90%. The inventive monoclonal antibodies are produced using a fluidized bed reactor in conjunction with a conventional protein-chemical purification method or preferably with a purification method involving less column chromatography. The monoclonal antibodies thus produced are suitable, in gamma-irradiated form, e.g. Tc-99m labelled, for the in vivo diagnosis of inflammatory diseases and bone marrow metastases. In alpha- or beta-irradiated form, e.g. astatine or Re-188 or Y-90 labelled form, the inventive monoclonal antibodies can be used, for example, in the treatment of leukemia.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.